Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ADMA BIOLOGICS, INC.

Get SEC filing alerts via email and in your feed for ADMA BIOLOGICS, INC.

ADMA

ADMA BIOLOGICS, INC.

About ADMA BIOLOGICS, INC.

ADMA Biologics, Inc. is a biopharmaceutical company specializing in the development and commercialization of plasma-derived therapeutics for immunocompromised patients. Its key products include ASCENIV and BIVIGAM, both FDA-approved intravenous immune globulin therapies. With a growing market projected to exceed $20 billion by 2030, ADMA targets patients with primary immunodeficiency diseases. The company is innovating with a yield enhancement process and expanding its product pipeline to address unmet medical needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ADMA BIOLOGICS, INC.

1
1
ADMA BIOLOGICS, INC. ADMA Biologics Reports Q1 2026 Financial Results with Increased Net Income and Revenue Decline

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ADMA BIOLOGICS, INC. ADMA Biologics Reports 20% Revenue Growth and Profitability for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ADMA BIOLOGICS, INC. ADMA Biologics Reports 12% Revenue Growth to $134.2 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ADMA BIOLOGICS, INC. ADMA Biologics Reports 14% Revenue Growth to $121.98 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ADMA BIOLOGICS, INC. ADMA Biologics Reports 40% Revenue Growth to $114.8 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ADMA BIOLOGICS, INC. ADMA Biologics Reports First GAAP Profit of $197.7 Million for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ADMA BIOLOGICS, INC. ADMA Biologics Reports 78% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments